Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of High-calcium Intake on Appetite, Insulinemia and Incretins

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01682343
Recruitment Status : Completed
First Posted : September 10, 2012
Last Update Posted : September 11, 2012
Sponsor:
Information provided by (Responsible Party):
Javier Gonzalez, Northumbria University

Brief Summary:
The purpose of this study is to investigate the appetite, insulin and incretin hormone responses to a high-calcium meal.

Condition or disease Intervention/treatment Phase
Nutritional and Metabolic Diseases Dietary Supplement: Calcium Not Applicable

Detailed Description:
Participants will be provided with control and high-calcium meals. Insulin, appetite, glucagon-like peptide-1 and glucose-dependent insulinotropic peptide responses will be assessed, along with rates of substrate oxidation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Effect of High-calcium Intake on Appetite, Insulinemia and Incretins
Study Start Date : May 2012
Actual Primary Completion Date : August 2012
Actual Study Completion Date : August 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Calcium

Arm Intervention/treatment
Placebo Comparator: Placebo
Breakfast consisting of milk-based porridge with a normal calcium content.
Experimental: High-Calcium
As control, but with a high-calcium content.
Dietary Supplement: Calcium
Milk-calcium supplement




Primary Outcome Measures :
  1. Subjective appetite ratings [ Time Frame: 3 hour ]
    Subjective ratings of appetite assessed by visual analogue scales.


Secondary Outcome Measures :
  1. Serum insulin concentration [ Time Frame: 2 hour ]
    2 hour area under the curve for serum insulin following breakfast consumption

  2. Plasma glucose-dependent insulinotropic peptide concentration [ Time Frame: 2 hour ]
    2 hour area under the curve for plasma glucose-dependent insulinotropic peptide following breakfast consumption

  3. Plasma glucagon-like peptide-1 concentration [ Time Frame: 2 hour ]
    2 hour area under the curve for plasma glucagon-like peptide-1 following breakfast consumption


Other Outcome Measures:
  1. Total fat oxidised during 60 min of exercise (g) [ Time Frame: 1 hour ]
    Assessed by indirect calorimetry



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • recreationally active
  • male

Exclusion Criteria:

  • food intolerances/allergies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01682343


Locations
Layout table for location information
United Kingdom
Northumbria University
Newcastle upon Tyne, Tyne on Wear, United Kingdom, NE1 8ST
Sponsors and Collaborators
Northumbria University
Investigators
Layout table for investigator information
Principal Investigator: Javier T Gonzalez, MRes Northumbria University

Layout table for additonal information
Responsible Party: Javier Gonzalez, PhD Student, Northumbria University
ClinicalTrials.gov Identifier: NCT01682343     History of Changes
Other Study ID Numbers: 32AN2
First Posted: September 10, 2012    Key Record Dates
Last Update Posted: September 11, 2012
Last Verified: September 2012

Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Diseases
Calcium
Calcium, Dietary
Incretins
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists